Clinical trials: Cancer, Breast
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
This phase I/II trial investigates the side effects of genetically engineered cells called FH-MagIC TCR-T cells and how well they work with atezolizumab in treating patients with triple negative breast cancer, urothelial cancer…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT04639245
- Testing
- Atezolizumab, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
- Trial name
- NCT02623972
- Testing
- Eribulin, Adriamycin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Estrogen Levels Among Breast Cancer Patients
Estradiol Levels in Patients Treated With Estring
Estrogen receptor positive breast cancer is the most common type of breast cancer and anti-estrogen therapy has been shown to be very effective in preventing recurrence.
- Trial name
- NCT01923298
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Arizona
Breast Cancer
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
This research study is studying a drug called GDC-0084 as a possible treatment for HER2-Positive Breast Cancer. The drugs involved in this study are: GDC-0084 Trastuzumab (Herceptin®)
- Trial name
- NCT03765983
- Testing
- Trastuzumab, GDC-0084
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression.
- Trial name
- NCT02659631
- Testing
- PF-06671008
- Where
- 9 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pfizer
Triple Negative Breast Neoplasms
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
- Trial name
- BEGONIA (NCT03742102)
- Testing
- Durvalumab, Capivasertib, Oleclumab
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 243 people
- Sponsor
- AstraZeneca
Colorectal Neoplasms, Neuroendocrine Tumors
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
This is a prospective pilot study designed to document safety and efficacy of liver-directed therapy for colorectal, neuroendocrine, cholangiocarcinoma, melanoma, and breast cancer metastases to the liver using Yttrium-90 glass…
- Conditions
- Colorectal Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Melanoma
- Trial name
- NCT01290536
- Testing
- Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)
- Volunteers
- 42 people
- Sponsor
- Nicholas Fidelman, MD
Anxiety Disorder, Breast Cancer
Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer
RATIONALE: Cranial microcurrent electrical stimulation (CES) is mild electrical current received through electrodes placed on the earlobes. CES may lessen symptoms in women with breast cancer receiving chemotherapy.
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Fatigue
- Trial name
- NCT00902330
- Testing
- energy-based therapy
- Volunteers
- 161 people
- Sponsor
- Virginia Commonwealth University
Atrophic Vaginitis, Breast Cancer
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
The purpose of this study is to see if Vagifem® 10mcg is safe for women who have had breast cancer. Vagifem is an estrogen product. It is a tiny tablet that is inserted into the vagina. It relieves vaginal dryness.
- Trial name
- NCT00984399
- Testing
- Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
DCIS
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
This is a feasibility study which will evaluate the effects of pre-operative treatment of DCIS of the breast with palbociclib. Patients with biopsy-proven DCIS are eligible for the study.
- Trial name
- WI223281 (NCT03535506)
- Testing
- Palbociclib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Georgetown University
Triple Negative Breast Cancer
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Prior to Amendment #7: The hypothesis of this study is that the combination of cabiralizumab and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating…
- Trial name
- NCT04331067
- Testing
- Paclitaxel, Carboplatin, Nivolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Breast Neoplasms, BRCA 1 Gene Mutation
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
The purpose of this 2-stage, 2-cohort Phase 2 trial is to evaluate the safety and efficacy of talazoparib (also known as BMN 673) in subjects with locally advanced or metastatic breast cancer with a deleterious germline BRCA 1 or…
- Conditions
- Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
- Trial name
- ABRAZO (NCT02034916)
- Testing
- talazoparib
- Where
- 71 sites in United States, France and 3 more
- Volunteers
- 84 people
- Sponsor
- Pfizer
Cancer, Breast
Translating Research Into Practice: Patient Navigation for Breast Cancer
The TRIP Project aims to overcome barriers to widespread implementation and dissemination of evidence-based practices that will improve the delivery of guideline-concordant care to vulnerable women with breast cancer.
- Trial name
- TRIP (NCT03514433)
- Testing
- TRIP Patient Navigation Intervention
- Where
- 5 sites in United States
- Volunteers
- 1,725 people
- Sponsor
- Boston Medical Center
Neuropathy, Pain
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
This randomized phase III trial studies calcium and magnesium to see how well they work in preventing peripheral neuropathy caused by ixabepilone in patients with breast cancer.
- Conditions
- Neuropathy, Pain, Recurrent Breast Carcinoma, Stage IV Breast Cancer
- Trial name
- NCT00998738
- Testing
- Calcium Gluconate, Magnesium Sulfate, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Breast Cancer
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00722072
- Testing
- fulvestrant, sorafenib tosylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer Metastatic
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2.
- Trial name
- NCT03321981
- Testing
- Zenocutuzumab, Trastuzumab, Vinorelbine
- Where
- 25 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Merus B.V.
Breast Cancer, Hot Flashes
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
RATIONALE: St. John's wort may help relieve hot flashes in women with breast cancer. PURPOSE: This phase II trial is studying how well St. John's wort works in relieving hot flashes in women with non-metastatic breast cancer.
- Trial name
- NCT00110136
- Testing
- St. John's Wort
- Where
- 19 sites in United States
- Volunteers
- 9 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
This is an open-label study to assess the safety, tolerability and efficacy of olaparib in combination with carboplatin. There are two parts in this study: Part A, a dose escalation in patients with advanced Human Epidermal…
- Trial name
- NCT02561832
- Testing
- Olaparib, Carboplatin, Anthracycline
- Where
- 7 sites in United States, Spain
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Breast Cancer
Vitamin D Supplementation in Women With DCIS and/or LCIS
The purpose of this study is to determine the safety and usefulness of oral Vitamin D supplementation in subjects with in situ carcinoma.
- Trial name
- NCT02936999
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Inova Health Care Services
Breast Cancer
Clinician Communication About Sexual Health
The objective of this study is to adapt a previously tested brief intervention aimed at enhancing clinicians communication about sexual health (iSHARE) to a mobile web-based platform showcasing a two-part podcast and to assess…
- Trial name
- NCT04262219
- Testing
- iShare
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center